Department of Neurosurgery, Salford Royal NHS Foundation Trust, Stott Lane, Salford, United Kingdom.
Neuro Oncol. 2013 Aug;15(8):1074-8. doi: 10.1093/neuonc/not033. Epub 2013 Mar 29.
In an exploratory subanalysis of the European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada (EORTC/NCIC) trial data, Gorlia et al. identified a variety of factors that were predictive of overall survival, including therapy administered, age, extent of surgery, mini-mental score, administration of corticosteroids, World Health Organization (WHO) performance status, and O-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. Gorlia et al. developed 3 nomograms, each intended to predict the survival times of patients with newly diagnosed glioblastoma on the basis of individual-specific combinations of prognostic factors. These are available online as a "GBM Calculator" and are intended for use in patient counseling. This study is an external validation of this calculator.
One hundred eighty-seven patients from 2 UK neurosurgical units who had histologically confirmed glioblastoma (WHO grade IV) had their information at diagnosis entered into the GBM calculator. A record was made of the actual and predicted median survival time for each patient. Statistical analysis was performed to assess the accuracy, precision, correlation, and discrimination of the calculator.
The calculator gives both inaccurate and imprecise predictions. Only 23% of predictions were within 25% of the actual survival, and the percentage bias is 140% in our series. The coefficient of variance is 76%, where a smaller percentage would indicate greater precision. There is only a weak positive correlation between the predicted and actual survival among patients (R(2) of 0.07). Discrimination is inadequate as measured by a C-index of 0.62.
The authors would not recommend the use of this tool in patient counseling. If departments were considering its use, we would advise that a similar validating exercise be undertaken.
在对欧洲癌症研究与治疗组织和加拿大国家癌症研究所(EORTC/NCIC)试验数据的探索性亚分析中,Gorlia 等人确定了多种预测总生存期的因素,包括所给予的治疗、年龄、手术范围、简易精神状态评分、皮质类固醇的应用、世界卫生组织(WHO)表现状态和 O-甲基鸟嘌呤-DNA 甲基转移酶(MGMT)启动子甲基化状态。Gorlia 等人开发了 3 个诺莫图,每个诺莫图旨在根据个体特定的预后因素组合预测新诊断为胶质母细胞瘤患者的生存时间。这些诺莫图可在线获得,作为“GBM 计算器”,并旨在用于患者咨询。本研究是对该计算器的外部验证。
来自 2 个英国神经外科中心的 187 名经组织学证实为胶质母细胞瘤(WHO 分级 IV)的患者,其诊断时的信息被输入 GBM 计算器。记录每位患者的实际和预测中位生存时间。进行了统计分析,以评估计算器的准确性、精度、相关性和区分度。
计算器的预测结果既不准确也不精确。只有 23%的预测值在实际生存时间的 25%以内,并且在我们的系列中,百分比偏差为 140%。变异系数为 76%,较小的百分比表示更高的精度。患者之间预测和实际生存之间仅存在微弱的正相关(R²为 0.07)。如 C 指数为 0.62 所示,区分度不足。
作者不建议在患者咨询中使用该工具。如果科室考虑使用该工具,我们建议进行类似的验证性研究。